Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 7/20 | 0.47 |
| ▸ | ACR | P10323 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 2/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10956570 | 0.87 | KMT2A (0.56) | KMT2APRSS1ACRMEN1SMN1; SMN2 | |
| SCHEMBL26047446 | 0.86 | PRSS1 (0.45) | KMT2APRSS1ACRMEN1SMN1; SMN2 | |
| SCHEMBL9617543 | 0.85 | HRH3 (0.54) | KMT2APRSS1ACRMEN1SMN1; SMN2 | |
| SCHEMBL20008761 | 0.85 | PRSS1 (0.62) | PRSS1ACRTMPRSS2F2 | |
| SCHEMBL11316711 | 0.83 | PARP10 (0.61) | KMT2APRSS1ACRMEN1SMN1; SMN2 | |
| SCHEMBL20008747 | 0.82 | KMT2A (0.49) | KMT2APRSS1ACRMEN1SMN1; SMN2 | |
| SCHEMBL7328271 | 0.82 | ACR (0.58) | KMT2APRSS1ACRMEN1SMN1; SMN2 | |
| SCHEMBL11569991 | 0.82 | KMT2A (0.54) | KMT2APRSS1ACRMEN1SMN1; SMN2 | |
| SCHEMBL3675089 | 0.81 | KMT2A (0.69) | KMT2APRSS1ACRMEN1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7330789 | 0.81 | ACR (0.59) | KMT2APRSS1ACRMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11154549-B2 | Opioid compositions resistant to overdose and abuse | ELYSIUM THERAPEUTICS, INC. (US) | 2021-10-26 | — | — | US | disclosed |
| US-20200093817-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2020-03-26 | — | — | US | disclosed |
| US-10335406-B2 | Opioid compositions resistant to overdose and abuse | ELYSIUM THERAPEUTICS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180085366-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20180085366-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200093817-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | OPRM1, OPRK1, OPRD1 | KMT2A 1946/4885PRSS1 952/4885ACR 4881/4885 |
| US-20180085366-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | OPRM1, OPRK1, OPRD1 | KMT2A 1946/4885PRSS1 952/4885ACR 4881/4885 |
| US-10335406-B2 | Opioid compositions resistant to overdose and abuse | OPRM1, OPRK1, OPRD1 | KMT2A 1946/4885PRSS1 952/4885ACR 4881/4885 |
| US-11154549-B2 | Opioid compositions resistant to overdose and abuse | OPRM1, OPRK1, OPRD1 | KMT2A 1946/4885PRSS1 952/4885ACR 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.